SNGX - Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity
Soligenix (SNGX) announced that it had achieved positive results in a phase 3 study treating patients with cutaneous T-cell lymphoma ((CTCL)). This was done using the company's drug known as SGX301. These positive results released were only the first batch for cycle 1, which only consisted of the first 8 weeks of treatment. These responses once again improved all the way out to 12 weeks. However, 12-week data for SGX-301 in this patient population won't be released until June of 2020. This will be another catalyst that investors should keep an eye on.